Articles tagged with Sarcoma
Researchers report a case of a 15-year-old boy with recurrent intrathoracic synovial sarcoma who achieved partial response with BRAF inhibitor Vemurafenib treatment. The study highlights the importance of routine next-generation sequencing to drive treatment choice and investigate BRAF mutations in SS tumors.
The NRG Oncology combined trial results indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma. pCR can be used as a prognostic factor for clinical outcomes in future STS research, with patients achieving higher overall and disease-free survival rates.
A new clinical trial has shown promising results for nirogacestat, a targeted drug that blocks the Notch protein. In the Phase 3 trial, 41% of patients' tumors significantly shrank after taking nirogacestat, with no growth in over 75%. The most common side effects were fatigue, gastrointestinal problems, and skin rashes.
Researchers have identified a new method to predict which sarcoma patients will benefit from a potential new treatment. By inhibiting the plk1 gene, they were able to target and slow down the growth of sarcoma cells. This breakthrough could lead to improved treatment options for sickest sarcoma patients in 5-10 years.
A systematic review and meta-analysis found that MRI-based surveillance after surgical treatment can detect clinically occult local recurrences, potentially improving patient outcomes. The study included 19 studies and showed a significant association between high-intensity surveillance and the detection of local recurrences.
Eleni Tomazou's project aims to create in vitro and in vivo models of pediatric sarcomas to accelerate drug discovery and precision medicine. Her work could lead to a significant impact on the treatment of these deadly cancers.
Scientists at Cold Spring Harbor Laboratory have found a way to reprogram cells causing Ewing sarcoma to behave like normal connective tissue cells. By blocking the protein ETV6, cancer cells can be forced to take on a new identity and grow less aggressively.
Researchers have created a genetic map to identify important genes causing sarcoma, a common childhood cancer. The study found that one in 14 individuals with sarcoma carries a clinically significant gene, offering hope for earlier diagnosis and treatment.
Researchers found that EWS::FLI1 induces Slit2 expression, which activates Robo receptors and enhances Ewing sarcoma growth. Silencing Slit2 strongly inhibited Ewing sarcoma cell growth, providing an opportunity for targeted therapy.
In a Phase I clinical trial, afami-cel achieved an objective response rate of 44% in patients with synovial sarcoma and 24% across all cancer types. The therapy demonstrated manageable toxicity and early activity in other cancer types, suggesting potential for solid tumors.
Scientists used AI-driven PandaOmics platform to analyze gene expression datasets from DNA repair diseases, identifying biomarkers associated with treatment response. The study focused on genes that stratify cancer patients by survival outcomes, providing potential targets for personalized therapies.
Researchers have identified two subgroups of Ewing sarcoma that respond differently to targeted drug therapy, with the first group responding to Linsitinib and AZD1775 treatment. The study suggests that repeated biopsies may be needed over time to determine the best course of treatment for each patient.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
Researchers found a significant increase in Kaposi's sarcoma incidence among young Black men in the South, with rates jumping by 3.3% per year. The study suggests that HIV infection and social determinants like poverty and lack of access to medical care contribute to this disparity.
Patients with non-metastatic soft tissue sarcoma can safely receive hypofractionated treatment over three weeks instead of five, achieving similar tumor control and no increased risk of wound complications. The study found comparable rates of major wound complications between the two treatment courses.
Scientists at IRB Barcelona and the PCCB have created a genetically tractable model of Ewing sarcoma using Drosophila flies expressing a mutant version of the human oncogene EWS-FLI. This model allows for the identification of critical proteins required for EWS-FLI's oncogenic function and potential therapeutic targets.
A recent study by Washington State University researchers has identified distinct genetic patterns among the most prevalent types of canine soft tissue sarcomas, potentially leading to more accurate diagnoses and effective treatments. The findings suggest that a single treatment approach may not be effective for all subtypes of the tumor.
A team of researchers from Ritsumeikan University in Japan has elucidated the mechanism behind the liquid-solid phase transition of FUS protein that leads to ALS. They discovered a new therapeutic target, arginine, which suppresses FUS aggregation and could delay ALS progression.
Researchers at Massachusetts General Hospital found that paclitaxel improves clinical outcomes and is cost-effective compared to commonly used treatments in Kenya. Using paclitaxel instead of bleomycin-vincristine could save 6,400 years-of-life and reduce healthcare expenditures by $3.7 million over five years.
Researchers have discovered a protein produced by soft-tissue sarcoma tumors that changes the biology of surrounding immune cells, promoting tumor growth. The study could lead to improved treatments for this rare and aggressive cancer type.
A Phase II study found that immunotherapy before surgery improved median progression-free survival and overall survival for undifferentiated pleomorphic sarcoma and recurrent dedifferentiated liposarcoma patients. The treatment also showed an association between intratumoral B-cell receptor repertoire and survival.
Researchers at Washington University School of Medicine have developed an investigational drug that targets synovial sarcoma, a rare and aggressive type of cancer. The drug, ACXT-3102, works by interfering with the metabolic pathway of the tumor cells, causing them to die from the buildup of reactive oxygen species.
A recent study found that nearly one-quarter of young sarcoma patients continue to use opioids after treatment is completed. The researchers highlight the need for monitoring and age-appropriate strategies to manage pain while minimizing opioid exposure.
A UC Davis study found a critical agent keeping KSHV dormant and undetected by the immune system. The virus is linked to various cancers and AIDS-related diseases. The researchers identified CHD4 as a key regulator of the latency-lytic switch, allowing the virus to stay silent.
A team of researchers has identified a biological pathway that drives genetic changes and bone metastasis in Ewing sarcoma, a rare childhood cancer. The study found that blocking the receptor Y5R can limit metastasis, offering new potential targets for treatment.
Researchers at UCSF developed a new technique using skin grafts with 'privacy glass' to provide a better facial color match for cancer patients. The study found that the technique resulted in a better match than other methods, with an average delta-E calculation of 6.3.
A phase 2 single-institution study found that dose-equivalent preoperative radiation therapy delivered in five days rather than over the conventional five weeks produced similar benefits and treatment side effects. The study showed excellent local control rates with acceptable toxicities and wound complications.
A retrospective cohort study of 27 patients with sarcoma lung metastases found high primary technical success rates for percutaneous image-guided microwave and cryoablation. The treatment modality and tumor location did not affect local progression, and smaller tumors showed lower cumulative incidence of local progression.
Researchers identified a protein called neurexin-1 in cancer stem-like cells that are resistant to chemotherapy and responsible for recurrence. Patients with higher levels of this protein have poorer outcomes and lower survival rates.
A new clinical guideline from ASTRO provides guidance on the use of radiation therapy to treat adult patients with soft tissue sarcoma, recommending optimal radiation dosing and techniques. The guideline also addresses the role of radiation therapy for retroperitoneal sarcomas.
Researchers repurpose cancer drug PLX3397 to combat sarcoma's growth and spread in animal models. The treatment inhibits CSF-1/CSF-1R signaling, reprogramming tumor-associated macrophages and stimulating immune cell infiltration.
Researchers at Huntsman Cancer Institute have identified a specific gene-regulating protein complex to target in the treatment of synovial sarcoma. The study provides new understanding of how the disease develops and spreads, offering potential breakthroughs in diagnosis and therapy.
Researchers at UNC Lineberger Comprehensive Cancer Center have discovered a gene, OTUD7A, linked to Ewing sarcoma, a bone cancer affecting mainly children. A compound, 7Ai, has shown promise in blocking OTUD7A protein activity and reducing tumor formation in mice.
Researchers have discovered a potential way to prevent Ewing sarcoma tumours from spreading by understanding how they develop a protective shield against the harsh environment of the bloodstream. This breakthrough may lead to the development of a clinical-grade immunotherapeutic treatment for Ewing sarcoma.
Adaptimmune Therapeutics plc reports initial data from its Phase 2 SPEARHEAD-1 trial showing a high response rate of 41.4% for patients with synovial sarcoma, including two complete responses and encouraging initial safety and durability. The trial's results support the company's BLA submission next year.
A new gene panel test developed by researchers allows for highly accurate diagnosis of liposarcoma types, distinguishing them from benign tumors and other cancers, with a success rate of 93% and costs of US$270 per case.
The study reveals that KDM5A and PHF2 positively control the expression of pro-metastatic genes in Ewing sarcoma. These genes include L1CAM, which promotes migratory and invasive properties. The researchers identified KDM5A and PHF2 as novel disease-promoting factors and potential new targets for metastasis inhibition.
Researchers discovered RING1B is critical for Ewing sarcoma development and hijacks transcriptional program to create cancerous cells. Epigenetic inhibitors may offer new treatment strategies.
Researchers found that chemotherapy is rarely used to treat adults with localized sarcoma, affecting only 22% of patients. Facilities performing more surgeries for sarcoma tend to use chemotherapy more frequently.
Scientists at Dana-Farber Cancer Institute discovered how an abnormal protein misdirects gene expression in cells, contributing to the growth of sarcoma tumors. The researchers found that a small segment of the SS18-SSX fusion protein binds to nucleosomes, leading to aberrant activation of genes.
Scientists have discovered a potential new target for treating Ewing sarcoma, a childhood cancer that affects the bone and soft tissue. The researchers found that an imbalance in genetic code-reading machines causes nucleoli to break up into smaller entities in Ewing sarcoma.
Researchers at UCLA Jonsson Comprehensive Cancer Center found a condensed five-day radiation regimen to be as effective as traditional five-week treatment in treating soft tissue sarcoma. The new approach showed lower wound complication rates and improved cancer control without increasing side effects.
Researchers found that B-cell markers were associated with improved overall survival in patients with advanced melanoma and soft-tissue sarcomas. B cells located within specialized immune-cell clusters (TLS) were predictive of response to checkpoint blockade, suggesting a dynamic interaction between immune components.
Scientists from the University of Pennsylvania School of Medicine have discovered a way to make sarcoma cells more susceptible to treatment by slowing down their growth through a key metabolic process. By reactivating the FBP2 enzyme, researchers were able to stop cancer cell proliferation and leave them vulnerable to targeted therapies.
Targeting HDAC2 with romidepsin inhibits MDM2 expression and promotes apoptosis in dedifferentiated liposarcoma. This approach may offer a new therapeutic avenue for treating this aggressive tumor type.
A study in mice showed that reducing a particular hormone signal can prevent the growth and spread of Ewing sarcoma, a bone cancer mainly found in teenagers. The findings suggest a potential treatment approach using existing drugs to neutralize glucocorticoid receptors.
A study published in Nature Communications reveals that inherited germline variations and somatic mutations interact to determine the course of Ewing sarcoma disease. The research, led by Dr. Thomas Grünewald, shows how genetic context influences tumor growth and progression.
Researchers have identified a combination of treatments that may be more powerful than current therapy alone for children with Ewing sarcoma. The new approach combines FAK inhibitors with aurora kinase B targets to kill cancer cells and inhibit tumor progression.
Researchers at Hiroshima University found that high levels of TIMP-1 increase liposarcoma tumor cell spread and aggression, while high TIMP-4 levels decrease migration and cell proliferation. This understanding can lead to new therapeutics and diagnostic methods for liposarcoma.
A new study has revealed a previously unknown interaction between proteins that causes certain types of cancer called sarcoma. The research, led by Pierre Åman, found that tumor-altered FET proteins bind to the SWI/SNF complex, leading to misregulation and disruptions in genetic programming.
Researchers at Karolinska Institutet identified four distinct molecular subtypes of undifferentiated uterine sarcoma, a rare and aggressive cancer, which could lead to improved treatment outcomes. The study also showed that some patients may live longer than initially predicted.
Researchers have identified the BRD9 protein as a key player in the growth and survival of synovial sarcoma cells. Degradation of this protein inhibits tumour progression, offering a potential therapeutic opportunity for treating this rare cancer.
Researchers identified the protein BRD9 as essential for the survival of synovial sarcoma tumours. They developed a new drug that degrades this protein, which is also responsible for driving cancer development, and found it to be effective in blocking tumour progression.
A study found that cancer patients are open to using complementary alternative medicines, but poorly informed about safety issues and risk of interactions with anti-cancer drugs. Vitamin D supplements were the most popular choice, followed by selenium plus zinc.
A study published in Cancer Immunology Research found that immune checkpoint inhibitors showed high efficacy and low toxicity in treating HIV-associated Kaposi's sarcoma. The treatment resulted in partial or complete remission in over 65% of patients, with limited side effects compared to standard chemotherapy.
A new assay has been developed to detect genetic abnormalities in sarcomas, which outperform conventional techniques in analysis of multiple target genes simultaneously. The assay was validated on 81 samples and showed high sensitivity, allowing for accurate diagnosis even in small sample sizes.
The study reveals how a fusion protein found in cancer cells enhances target gene expression by converting microsatellite repeats into active enhancers. Blocking this process prevents tumor growth.
PharmaMar will present data on Yondelis and lurbinectedin, showcasing clinical advances in soft tissue sarcoma, breast cancer, and small-cell lung cancer. The company's molecules have demonstrated efficacy and safety in various studies, including a phase III trial for small-cell lung cancer.
IDIBELL researchers discover EphA2 membrane receptor's role in tumor aggressiveness and metastasis in Ewing sarcoma. The study finds that blocking this receptor activity can significantly decrease metastases incidence and survival rates.
Scientists at Greehey Children's Cancer Research Institute have found a new mechanism by which BRCA1 can be rendered dysfunctional in Ewing sarcoma. The study reveals that the mutant oncogene produced by the fusion oncogene traps BRCA1, preventing it from repairing genetic damage.